Aarti Pharmalabs cash flow

Latest FY26

Cash from operations: ₹262cr−21.0% on FY25
Capital spending: ₹409cr+1.8% on FY25
Free cash flow: −₹147cr−₹70.5 cr in FY25
Cash from financing: ₹171cr+160.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	104	86.9	73.2	62.5
	—	7.1	13.5	0.0	0.0
	—	46.9	26.9	17.2	21.1
	—	−2.1	−7.1	−3.0	−0.5
	—	0.0	−0.1	−0.0	−1.3
	—	2.5	0.0	0.0	0.0
	—	34.7	0.0	0.0	0.0
	—	2.8	1.3	7.3	0.0
	—	−7.6	0.0	0.0	0.0
	—	−80.6	55.3	−39.7	−127
	—	−97.0	−84.4	−126	−20.8
	—	2.6	0.0	0.0	0.0
	—	70.2	−56.9	43.3	130
Cash from operating activities
	316	225	361	300	261
	—	83.9	35.4	−27.2	64.6
	—	309	396	273	325
	—	46.9	64.5	56.9	62.4
	—	262	332	216	263
Cash from investing activities
	—	409	402	156	120
	—	0.0	0.0	43.2	0.0
	—	38.9	41.8	0.0	0.0
	—	0.0	0.0	0.0	38.7
	—	0.0	0.0	0.0	−0.5
	—	12.5	22.8	0.0	0.0
	—	2.9	0.0	0.0	0.0
	—	0.0	0.1	0.0	0.0
	—	2.1	7.1	3.0	0.9
	—	0.0	0.0	−18.9	0.0
	—	−431	−414	−215	−158
Cash from financing activities
	—	0.0	0.0	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	264	128	50.0	−124
	—	18.7	6.2	0.0	0.0
	—	—	—	4.9	0.0
	—	38.7	24.5	17.2	0.0
	—	36.3	31.7	18.1	0.0
	—	0.0	0.0	0.0	21.1
	—	0.0	0.0	0.0	−18.1
	—	171	65.4	9.7	−163
	—	1.8	−16.9	11.5	−58.3
	—	1.8	−16.9	11.5	−58.3
	—	—	—	23.6	25.0
Reference items
	487	369	464	386	342
	22.5%	20.3%	22.0%	20.8%	17.6%
	−147	−147	−70.5	17.6	143
	—	103	37.3	50.5	—
	−₹16.26	−₹16.26	−₹7.77	₹1.94	₹15.81
	—	1.50×	1.22×	1.00×	1.36×
	—	46.9	64.5	56.9	62.4
	—	38.7	24.5	17.2	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIPHARM₹823.65

Aarti Pharmalabs Ltd.

· Pharma & Health

₹ CrorePeersAARTIDRUGS ADVENZYMES AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹7,467 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	62.5	73.2	86.9	104.3	—
+ Impairment Loss / (Reversal)	0.0	0.0	13.5	7.1	—
+ Finance Costs	21.1	17.2	26.9	46.9	—
+ Interest Income	-0.5	-3.0	-7.1	-2.1	—
+ Dividend Income	-1.3	-0.0	-0.1	0.0	—
+ Share-based Payments	0.0	0.0	0.0	2.5	—
+ Unrealised FX (Gain) / Loss	0.0	0.0	0.0	34.7	—
+ Other Non-cash Items	0.0	7.3	1.3	2.8	—
+ Other Reconciling Items	0.0	0.0	0.0	-7.6	—
Changes in Working Capital
+ Inventories	-126.7	-39.7	55.3	-80.6	—
+ Trade Receivables — Current	-20.8	-125.5	-84.4	-97.0	—
+ Other Non-current Assets	0.0	0.0	0.0	2.6	—
+ Trade Payables — Current	130.2	43.3	-56.9	70.2	—
Cash from Operating Activities
Profit Before Tax (per I/S)	260.8	300.5	360.7	224.9	315.9
+ Total Adjustments (incl. Working Capital)	64.6	-27.2	35.4	83.9	—
Cash from Operations (pre-tax)	325.4	273.3	396.1	308.9	—
+ Income Taxes Paid	62.4	56.9	64.5	46.9	—
Cash from Operating Activities	263.0	216.4	331.6	261.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	119.7	155.6	402.0	409.4	—
+ Acq of Intangible Assets	0.0	43.2	0.0	0.0	—
+ Acq of Intangibles under Development	0.0	0.0	41.8	38.9	—
+ Acq of Investment Property	38.7	0.0	0.0	0.0	—
+ Disp of Investment Property	-0.5	0.0	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	0.0	0.0	22.8	12.5	—
+ Loans & Advances Repaid	0.0	0.0	0.0	2.9	—
+ Dividends Received — Investing	0.0	0.0	0.1	0.0	—
+ Interest Received — Investing	0.9	3.0	7.1	2.1	—
+ Other Inflows / (Outflows) — Investing	0.0	-18.9	0.0	0.0	—
Cash from Investing Activities	-157.8	-214.6	-413.9	-430.7	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.0	0.0	—
+ Proceeds from Borrowings	-124.3	50.0	127.9	264.2	—
+ Payment of Lease Liabilities	0.0	0.0	6.2	18.7	—
+ Payment of Finance Lease Liabilities	0.0	4.9	—	—	—
+ Interest Paid	0.0	17.2	24.5	38.7	—
+ Dividends Paid	0.0	18.1	31.7	36.3	—
+ Income Taxes (Paid) / Refund — Financing	21.1	0.0	0.0	0.0	—
+ Other Inflows / (Outflows) — Financing	-18.1	0.0	0.0	0.0	—
Cash from Financing Activities	-163.5	9.7	65.4	170.6	—
Net Changes in Cash (pre-FX)	-58.3	11.5	-16.9	1.8	—
Net Changes in Cash	-58.3	11.5	-16.9	1.8	—
Closing Cash	25.0	23.6	—	—	—
Reference Items
EBITDA	342.0	386.0	464.4	369.2	486.7
EBITDA Margin %	17.58	20.84	21.96	20.29	22.52
Free Cash Flow (CFO − Capex)	143.4	17.6	-70.5	-147.4	-147.4
Free Cash Flow to Equity	—	50.5	37.3	103.1	—
Free Cash Flow per Basic Share	15.81	1.94	-7.77	-16.26	-16.26
Cash Flow to Net Income	1.36	1.00	1.22	1.50	—
Cash Paid for Taxes	62.4	56.9	64.5	46.9	—
Cash Paid for Interest	—	17.2	24.5	38.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.